Tebentafusp
Based on 1 Customer Validation
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A*02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells.
For research use only. We do not sell to patients.
- Purity: 99.90%
- CAS No.: 1874157-95-5
- Molecular Weight:76.16 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
scFv-kappa-heavy-TR-BETA-2_TR-ALPHA
Human
CD3E & PMEL
Tebentafusp is an ImmTAC recognizing a peptide derived from the melanoma-specific protein, gp100, presented by HLA-A*0201[3].
Tebentafusp (31 pM, 82 pM, and 131 pM; 16 h) stimulates cytotoxic degranulation activity of PBMC against Mel526 cells rather than gp100-negative A375 cells[3].
Tebentafusp (100 pM; 0-50 h) mediates CD8+ T cell killing despite the presence of regulatory T cells via monitoring caspase 3/7 activation during 40-48 hr[3].
Tebentafusp (100 pM; 0-80 h) triggers cytolysis of melanoma cells by CD4+ T cell subpopulations[3].
Tebentafusp (1, 12, 31, 82, and 131 pM; 24 h or 96 h) increases granzyme B amount, and induces broad cytokine and chemokine release including in both CD4+ and CD8+ cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
scFv-TR-Alpha_Beta-2
ELISA, FACS, Functional assay
-
Loaded HLA-A*0201 GP100 Complex Protein, Human (Biotinylated, YLEPGPVTA, HEK293, His-Avi, HY-P77754) on NTA biosensor, can bind Tebentafusp with an affinity constant of 7.761E-10 M as determined in BLI assay. -
Flow cytometric analysis of 1×106 Jurkat cells labelling CD3E (red) with Tebentafusp (HY-P99339). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control.
Chemical Information
-
CAS No. 1874157-95-5
-
Appearance Liquid
-
Molecular Weight 76.16 kDa
-
Color Colorless to light yellow
-
SMILES
[Tebentafusp]
-
Synonyms
IMCgp100
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Middleton MR, et al. Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. Clin Cancer Res. 2020 Nov 15;26(22):5869-5878. [Content Brief]
[2]. Dhillon S. Tebentafusp: First Approval. Drugs. 2022 Apr;82(6):703-710. [Content Brief]
[3]. Boudousquie C, et al. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells. Immunology. 2017 Nov;152(3):425-438. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)